Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 184

1.

A study of JAK2 (V617F) gene mutation in patients with chronic myeloproliferative disorders.

Hamidah NH, Farisah NR, Azlinda AB, Wong FL, Das S, Fadillah SA, Ainoon O.

Clin Ter. 2012;163(2):109-13.

PMID:
22555824
2.

The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.

Michiels JJ, De Raeve H, Berneman Z, Van Bockstaele D, Hebeda K, Lam K, Schroyens W.

Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):307-40. Review.

PMID:
16810609
3.

Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders.

Langabeer SE, Ni Ainle F, Conneally E, Lawler M.

Ir J Med Sci. 2007 Jul-Sep;176(2):105-9. Epub 2007 Apr 18.

PMID:
17440677
4.

JAK2-V617F mutation in Moroccan patients with myeloproliferative disorders: contribution, diagnosis and therapeutic prospects.

Benmoussa A, Dehbi H, Fehri S, Quessar A, Nadifi S.

Pathol Biol (Paris). 2011 Aug;59(4):e89-92. doi: 10.1016/j.patbio.2009.06.005. Epub 2009 Nov 24.

PMID:
19939582
5.

Quantitative assay for Janus kinase 2 (JAK2) mutation in Chinese patients with chronic myeloproliferative disorders.

Shen YM, Chao HY, Zhang R, Feng YF, Cen JN, Yao L, Shen HJ, Zhu ZL, Xue YQ.

J Int Med Res. 2009 Jan-Feb;37(1):37-46.

PMID:
19215672
6.

Rapid identification of heterozygous or homozygous JAK2(V617F) mutations in myeloproliferative neoplasms using melting curve analysis.

Ho CL, Wu YY, Hung HM, Chang PY, Kao WY, Chen YC, Chao TY.

J Formos Med Assoc. 2012 Jan;111(1):34-40. doi: 10.1016/j.jfma.2012.01.003. Epub 2012 Feb 1.

7.

Prevalence of the JAK2-V617F mutation in Taiwanese patients with chronic myeloproliferative disorders.

Lieu CH, Wu HS, Hon YC, Tsai WH, Yang CF, Wang CC, Lin YC, Shih CH, Hsu HC.

Intern Med J. 2008 Jun;38(6):422-6. doi: 10.1111/j.1445-5994.2007.01589.x. Epub 2008 Mar 7.

PMID:
18336541
8.
9.

[Usefulness of real-time semi-quantitative PCR, JAK2 MutaScreen kit for JAK2 V617F screening].

Chae H, Lee JH, Lim J, Jung SW, Kim M, Kim Y, Han K, Cho BS, Cho SG, Lee JW, Min WS.

Korean J Lab Med. 2009 Jun;29(3):243-8. doi: 10.3343/kjlm.2009.29.3.243. Korean.

10.

The incidence of JAK2 V617F mutation in bcr/abl-negative chronic myeloproliferative disorders: assessment by two different detection methods.

Lucia E, Martino B, Mammi C, Vigna E, Mazzone C, Gentile M, Qualtieri G, Bisconte MG, Naccarato M, Gentile C, Laganà C, Romeo F, Neri A, Nobile F, Morabito F.

Leuk Lymphoma. 2008 Oct;49(10):1907-15. doi: 10.1080/10428190802290652.

PMID:
18720212
11.

Evaluation of the JAK2-V617F gene mutation in Turkish patients with essential thrombocythemia and polycythemia vera.

Karkucak M, Yakut T, Ozkocaman V, Ozkalemkas F, Ali R, Bayram M, Gorukmez O, Ocakoglu G.

Mol Biol Rep. 2012 Sep;39(9):8663-7. doi: 10.1007/s11033-012-1721-x. Epub 2012 Jun 22.

PMID:
22722988
12.

Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation.

Bang SM, Lee JS, Ahn JY, Lee JH, Hyun MS, Kim BS, Park MR, Chi HS, Kim HY, Kim HJ, Lee MH, Kim H, Won JH, Yoon HJ, Oh DY, Nam EM, Bae SH, Kim BK; Korean MPN Working Party.

Thromb Haemost. 2009 Mar;101(3):547-51.

PMID:
19277418
13.

[The investigation of JAK2 V617F point mutation in myeloproliferative disorders by allele-specific polymerase chain reaction in combination with sequence analysis].

Zhang SJ, Li WD, Song JH, Xu W, Qiu HX, Li JY.

Zhonghua Yi Xue Za Zhi. 2007 Aug 14;87(30):2109-12. Chinese.

PMID:
17988529
14.

[Clinical study on relationship between JAK2 V617F mutation and chronic myeloproliferative disorders].

Zhang Y, Li L, Nie L, Yu Y, Yang YH, Zhang ZQ, Yang L, Xu SC, Xiao ZJ.

Zhonghua Xue Ye Xue Za Zhi. 2008 Feb;29(2):105-9. Chinese.

PMID:
18681311
15.

Detection of the JAK2 V617F missense mutation by high resolution melting analysis and its validation.

Er TK, Lin SF, Chang JG, Hsieh LL, Lin SK, Wang LH, Lin CW, Chang CS, Liu TC.

Clin Chim Acta. 2009 Oct;408(1-2):39-44. doi: 10.1016/j.cca.2009.07.002. Epub 2009 Jul 10.

PMID:
19595684
16.

Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens.

Moliterno AR, Williams DM, Rogers O, Isaacs MA, Spivak JL.

Exp Hematol. 2008 Nov;36(11):1480-6. doi: 10.1016/j.exphem.2008.05.006. Epub 2008 Aug 23.

17.

The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis.

Colaizzo D, Amitrano L, Tiscia GL, Scenna G, Grandone E, Guardascione MA, Brancaccio V, Margaglione M.

J Thromb Haemost. 2007 Jan;5(1):55-61. Epub 2006 Oct 20.

18.

JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders.

Rumi E, Passamonti F, Pietra D, Della Porta MG, Arcaini L, Boggi S, Elena C, Boveri E, Pascutto C, Lazzarino M, Cazzola M.

Cancer. 2006 Nov 1;107(9):2206-11.

19.

Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression.

Moliterno AR, Williams DM, Rogers O, Spivak JL.

Blood. 2006 Dec 1;108(12):3913-5. Epub 2006 Aug 15.

20.

The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more "erythremic" and less "thrombocythemic": a molecular, histologic, and clinical study.

Rudzki Z, Sacha T, Stój A, Czekalska S, Wójcik M, Skotnicki AB, Grabowska B, Zduńczyk A, Okoń K, Stachura J.

Int J Hematol. 2007 Aug;86(2):130-6.

PMID:
17875526
Items per page

Supplemental Content

Write to the Help Desk